Many important medicines and medical technologies began in university laboratories. When those discoveries reach patients, the institutions that made them possible often receive royalties. Understanding how those royalties come to exist explains why they are a distinctive asset, and why institutions sometimes choose to sell them.
This explainer follows a royalty from its origin in research through licensing, development and commercialization, then looks at the reasons an institution might monetize it and the questions worth asking along the way.
From discovery to license
In the United States, the Bayh-Dole Act of 1980 allows universities and other nonprofit institutions to own inventions made with federal research funding and to license them to companies. Before the law, rights to many federally funded inventions remained with the government, and relatively few were developed into products. Bayh-Dole gave institutions both the ownership and the incentive to move discoveries toward commercial use.
A university's technology transfer office typically files patents on promising discoveries and negotiates licenses with companies that can develop them. The licensee might be an established pharmaceutical company, a mid-sized specialty firm or a startup formed around the invention, sometimes with the faculty inventor as a founder or adviser.
Anatomy of a license
Those licenses often include upfront fees, milestone payments as development progresses and a royalty on net sales if a product reaches the market. The details vary widely, and they determine what the royalty will be worth if the product succeeds.
- Royalty rate: a percentage of net sales, sometimes tiered so the rate changes as annual sales cross defined levels.
- Royalty term: how long payments last, often tied to the expiration of the licensed patents in each country, or to a fixed period after first sale.
- Net sales definition: which deductions, such as discounts, rebates and returns, are subtracted before the royalty is calculated.
- Sublicense income: the share the institution receives if the licensee sublicenses the technology to another company.
- Royalty stacking: provisions that reduce the rate if the licensee must also pay royalties to other patent holders.
- Diligence obligations: commitments by the licensee to develop and commercialize the technology, with remedies if it does not.
A royalty stream is only as clear as the license that creates it. Two products with similar sales can produce very different royalties depending on the rate tiers, the deductions allowed, the stacking provisions and the term.
A long road
The path from license to approved product can take a decade or more, and most licensed technologies never reach the market. Clinical trials can fail, a licensee can change strategy, or a competing product can make the program unattractive. Institutions often license many technologies knowing that only a few will produce meaningful income.
When one does, the royalty can become a significant, long-lived income stream, but one that depends on the product's sales, its patent life and the commercial decisions of the licensee. The institution usually has no role in pricing, marketing or manufacturing. It receives reports and payments, and it relies on audit rights to confirm they are correct.
A royalty is a share of someone else's success, paid over a long time.
That is the essential character of the asset. A royalty is a share of someone else's success, paid over a long time. Some institutions prefer to have more of it now.
What makes a royalty distinctive
A royalty on an approved product has unusual features for an institutional asset. It requires no ongoing investment from the holder, because the licensee bears the costs of manufacturing, selling and supporting the product. Its payments are linked to sales, not to the licensee's profits, so a licensee's spending decisions elsewhere do not directly reduce it.
It also has a finite life. Payments usually decline or end as patents expire and competitors enter, so the royalty is a wasting asset rather than a perpetual one. Its value is concentrated in a single product, exposed to that product's clinical, regulatory and commercial fortunes. Those features are why a royalty can be both highly valuable and difficult for an institution to hold comfortably.
Valuation follows from the same features. A buyer forecasts the product's sales over the remaining royalty term, applies the license terms to calculate payments, and weighs the risks that could change either. Small differences in assumptions about patent life or competition can produce large differences in value, which is why transparency about assumptions matters.
How proceeds are shared
Bayh-Dole requires institutions to share royalties with inventors and to use the remaining income, after the costs of administering inventions, for scientific research or education. Each institution sets its own policy within that framework. A common pattern divides net income among the inventors, their department or school, and the central institution or its research programs.
These sharing arrangements matter when an institution considers a monetization. Proceeds from a sale must flow through the same policy, and inventors and departments often have a strong interest in how and when that happens. A transaction that ignores those stakeholders can create friction even if the price is fair.
Why institutions monetize
- To fund new research, facilities or programs today rather than waiting for royalty payments over many years.
- To diversify an endowment that has become concentrated in a single product's performance.
- To reduce exposure to risks the institution cannot control, such as competition or patent challenges.
- To share proceeds with inventors and departments on a defined schedule.
The decision is rarely only financial. A university may want to build a new research center while the opportunity exists, or it may recognize that a single product now represents an outsized share of its income. Monetizing converts an uncertain future stream into a known amount the institution can put to work on its own timetable.
Ways to structure a sale
A monetization does not have to be all or nothing. Institutions can tailor a transaction to how much risk they want to keep and how much liquidity they need.
- Selling the entire royalty interest for a single upfront payment.
- Selling a percentage of the royalty and keeping the rest, so the institution continues to share in the product's performance.
- Selling payments for a defined period or up to a defined total, after which the royalty reverts to the institution.
- Selling only payments above or below a certain annual level, so the institution keeps a floor or retains the upside.
The right structure depends on what the institution is trying to achieve. An institution funding a specific project may need a defined amount by a defined date. One concerned mainly with concentration may prefer to sell a portion and keep meaningful exposure. Partial and time-limited structures can also help align a transaction with internal stakeholders who want to keep sharing in the product's success.
In most royalty sales, the institution sells the right to receive payments rather than the underlying patents or the license itself. The institution typically remains the licensor, keeps its relationship with the licensee and retains its obligations under the license and under federal law.
An institution considering a sale should understand how a buyer reaches its valuation, not only the number it offers. A few questions help.
What sales forecast does the valuation assume, and what are the main risks the buyer has identified? How does it treat patent expiration, potential challenges and regulatory exclusivity? How will the transaction respect the institution's royalty-sharing policy, its relationship with the licensee and its obligations under Bayh-Dole? And what information will the buyer need after closing, and who will handle audits and reporting?
Common mistakes
One common mistake is waiting until the institution needs the money. A sale run under time pressure gives the institution less room to compare offers or consider partial structures. Another is underestimating the importance of the license documents. Ambiguous net sales definitions, missing audit rights or unclear stacking provisions can reduce what a buyer is willing to pay.
A third is overlooking internal stakeholders. Faculty inventors, department chairs, trustees and the technology transfer office all have a view, and aligning them early makes the process smoother.
What a good counterparty brings
Valuing a royalty requires understanding the science, the market, the patent position, the license terms and the licensee. Institutions benefit from counterparties who do that work rigorously, explain their assumptions and structure transactions that fit the institution's goals, whether that means selling all of a royalty, part of it, or only payments above a certain level.
A good counterparty also respects the institution's relationships. The licensee is often a long-term partner of the university, sometimes a company founded by its own faculty. A buyer should be able to receive reports and exercise rights without disrupting that relationship. It should also be comfortable working within the institution's governance, from the technology transfer office to the board, on the institution's timetable.
UpManagement Crucible is being built with these transactions in mind, with academic royalty solutions designed to respect Bayh-Dole and institutional mission, and with dedicated coverage of technology transfer offices and royalty holders from its offices in Dallas, Washington, D.C. and Houston. It is an investor and financier, not a drug developer.
Crucible is a platform in formation. Its investment adviser registration and other approvals are not yet in place.
This article is for general information only. It is not an offer to sell, or a solicitation of an offer to buy, any security or investment product, and nothing on this site markets any investment.
Published by UpManagement. This article is general information about the sectors in which the UpManagement companies operate. It is not legal, tax, investment or compliance advice, and it is not an offer to sell or a solicitation of an offer to buy any security. Where a company is described as a platform in formation, its approvals are not yet in place.
